Huminsulin 30/70 Solution for Injection 40IU/ml is a premixed insulin formulation containing 70% insulin isophane (NPH insulin) and 30% human insulin, designed for subcutaneous administration to improve glycemic control in patients with diabetes mellitus. The intermediate-acting insulin isophane component provides a prolonged duration of action, while the soluble human insulin offers a rapid onset, facilitating both basal and prandial glucose regulation. This biphasic insulin preparation is indicated for adults and children with type 1 or type 2 diabetes requiring insulin therapy when diet, exercise, and oral hypoglycemic agents alone do not achieve adequate glycemic control. Huminsulin 30/70 should be administered subcutaneously, typically before meals, with dosing individualized based on blood glucose monitoring and clinical response. It is essential to rotate injection sites to minimize the risk of lipodystrophy. Caution is advised to avoid hypoglycemia, the most common adverse effect, by adjusting dosage in accordance with meal patterns, physical activity, and concomitant medications. Patients should be educated on recognizing and managing hypoglycemia and hyperglycemia. Huminsulin 30/70 is contraindicated in patients with hypersensitivity to insulin or any excipients. Proper storage and handling are necessary to maintain insulin potency and efficacy.